Haisco Pharmaceutical Group Co., Ltd. (SHE:002653)
62.59
-0.01 (-0.02%)
Sep 11, 2026, 3:04 PM CST
SHE:002653 Revenue
Haisco Pharmaceutical Group had revenue of 1.53B CNY in the quarter ending June 30, 2026, with 38.13% growth. This brings the company's revenue in the last twelve months to 5.48B, up 35.86% year-over-year. In the year 2025, Haisco Pharmaceutical Group had annual revenue of 4.39B with 17.91% growth.
Revenue (ttm)
5.48B
Revenue Growth
+35.86%
P/S Ratio
12.66
Revenue / Employee
979.55K
Employees
5,597
Market Cap
69.43B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 4.39B | 666.44M | 17.91% |
| Dec 31, 2024 | 3.72B | 366.28M | 10.92% |
| Dec 31, 2023 | 3.36B | 339.78M | 11.27% |
| Jan 1, 2023 | 3.02B | 241.98M | 8.73% |
| Jan 1, 2022 | 2.77B | -556.28M | -16.71% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
Revenue RankingsHaisco Pharmaceutical Group News
- 16 days ago - Haisco Pharmaceutical Group Quarterly report: Q2 2026 - Filings
- 17 days ago - Haisco Enters $1.5 Billion Exclusive License Agreement With Sentivera - Nasdaq
- 2 months ago - Nuvectis gains two experimental drugs in licensing deal with China's Haisco - Reuters
- 3 months ago - Haisco Announces Licensing And Research Collaboration With Lilly - Nasdaq
- 4 months ago - Haisco Pharmaceutical Group Quarterly report: Q1 2026 - Filings
- 4 months ago - Haisco Pharmaceutical Group Annual report: Q4 2025 - Filings
- 4 months ago - As China’s biotech firms shift gears, can AI floor the accelerator? - South China Morning Post
- 10 months ago - Haisco Pharmaceutical Group Quarterly report: Q3 2025 - Filings